Suppr超能文献

复杂经皮冠状动脉介入治疗特征对合并或不合并慢性肾脏病患者临床结局的影响。

Impact of complex percutaneous coronary intervention features on clinical outcomes in patients with or without chronic kidney disease.

作者信息

Chen Huazhen, Spirito Alessandro, Sartori Samantha, Nicolas Johny, Cao Davide, Zhang Zhongjie, Baber Usman, Kamaleldin Karim, Guthrie Jeffers, Vogel Birgit, Sweeny Joseph, Krishnan Prakash, Sharma Samin K, Kini Annapoorna, Dangas George, Mehran Roxana

机构信息

The Zena and Michael A. Wiener Cardiovascular institute, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.

University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.

出版信息

Catheter Cardiovasc Interv. 2023 Feb;101(3):511-519. doi: 10.1002/ccd.30569. Epub 2023 Jan 24.

Abstract

BACKGROUND

Patients with chronic kidney disease (CKD) are at higher risk of ischemic and bleeding events after percutaneous coronary intervention (PCI). Complex PCI (CPCI) is associated with higher rates of ischemic complications. Whether CPCI confers an additive risk of adverse events in CKD patients is unclear.

METHODS

Patients who underwent PCI at a single tertiary-care-center between 2012 and 2019 were stratified by CKD status and CPCI. The primary outcome was major adverse cardiac events (MACE), a composite of all-cause death, myocardial infarction (MI), and target-vessel revascularization (TVR) at 1-year follow-up. Secondary outcomes included the individual components of the primary outcome and major bleeding.

RESULTS

Out of 15,071 patients, 4537 (30.1%) had CKD and 10,534 (69.9%) had no CKD. Patients undergoing CPCI were 1151 (25.4%) and 2983 (28.3%) in the two cohorts, respectively. At one year, CPCI compared with no CPCI was associated with higher risk of MACE in both CKD (Adj. HR 1.72, 95% confidence interval [CI] 1.45-2.06, p < 0.001) and no-CKD patients (Adj. hazard ratios [HR] 2.19, 95% CI 1.91-2.51, p < 0.001; p of interaction 0.057), determined by an excess of death, MI and TVR in CKD patients and of TVR and MI only in no-CKD. CPCI was related with a consistent increase of major bleeding in the CKD (Adj. HR 1.49, 95% CI 1.18-1.87, p < 0.001) and no-CKD group (Adj. HR 1.23, 95% CI 0.98-1.54, p = 0.071, p of interaction 0.206).

CONCLUSION

At 1-year follow-up, CPCI was associated with higher risk of MACE and major bleeding irrespective of concomitant CKD. CPCI predicted mortality in CKD patients only.

摘要

背景

慢性肾脏病(CKD)患者在经皮冠状动脉介入治疗(PCI)后发生缺血和出血事件的风险更高。复杂PCI(CPCI)与更高的缺血并发症发生率相关。CPCI是否会增加CKD患者不良事件的风险尚不清楚。

方法

2012年至2019年在一家三级医疗中心接受PCI的患者按CKD状态和CPCI进行分层。主要结局是主要不良心脏事件(MACE),即1年随访时全因死亡、心肌梗死(MI)和靶血管血运重建(TVR)的复合结局。次要结局包括主要结局的各个组成部分以及大出血。

结果

在15071例患者中,4537例(30.1%)患有CKD,10534例(69.9%)没有CKD。两个队列中接受CPCI的患者分别为1151例(25.4%)和2983例(28.3%)。在1年时,与未接受CPCI相比,CPCI在CKD患者(调整后风险比[HR]1.72,95%置信区间[CI]1.45 - 2.06,p < 0.001)和非CKD患者中(调整后HR 2.19,95% CI 1.91 - 2.51,p < 0.001;交互作用p值0.057)均与更高的MACE风险相关,这是由CKD患者中死亡、MI和TVR增加以及非CKD患者中仅TVR和MI增加所决定的。CPCI与CKD组(调整后HR 1.49,95% CI 1.18 - 1.87,p < 0.001)和非CKD组(调整后HR 1.23,95% CI 0.98 - 1.54,p = 0.071,交互作用p值0.206)大出血的持续增加相关。

结论

在1年随访时,无论是否合并CKD,CPCI都与更高的MACE和大出血风险相关。CPCI仅可预测CKD患者的死亡率。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验